Skip to content

Medical cannabis in Israel

A licence or a prescription, under Ministry of Health rules • Not a registered medicine, and not legalization

Kicker: Background, history and policy

Title: Medical cannabis in Israel

Dek: What it is, how the Israeli system works, and the story that brought it here.

Medical cannabis in Israel is cannabis that may be used for medical purposes under a licence or a prescription issued according to law. The field is supervised by the Ministry of Health and the Israel Medical Cannabis Agency (IMCA, known in Hebrew as יק״ר, the medical cannabis unit at the ministry). Products are bought in licensed pharmacies. According to the IMCA situation report for September 2026, as reported by the magazine on 11 November 2026 (article 289059), the number of patients stood at 142,000 in September, after a peak of 145,700 in August. Of those, 107,474 held an active licence and about 34,500 received a prescription through the health funds.

Depending on the indication and the medical conditions, approval is given on a prescription track or on a licence track. Eligibility is not automatic, and cannabis itself is not a registered medicine in Israel. Medical regulation is also not legalization: use outside the terms of the licence or prescription remains subject to the law. This page gathers the background, the history and the research. Up-to-date guides on eligibility, the process and pharmacy stock live on Cannabiz (in Hebrew): products and price comparison, pharmacies, and an index of licensed doctors.

How it works today

Approval starts with a medical examination. Depending on the indication and the conditions that have been set, a patient may receive a prescription through the relevant track in the health funds (Kupot Holim, Israel's public health-insurance organizations), or an IMCA licence. Both tracks require a decision by an authorized clinician. A diagnosis, on its own, does not guarantee approval.

Practical information changes, and is therefore kept on Cannabiz (Hebrew): who may be eligible, the licence and prescription process, and pharmacy stock lookup. The governing source is the current Ministry of Health procedure and the instructions given to the patient.

Short questions

What is medical cannabis in Israel?
It is the use of cannabis for medical purposes under a licence or a prescription issued according to law, supervised by the Ministry of Health and IMCA. Cannabis itself is not a registered medicine, and approval is given according to medical and regulatory conditions. For ongoing news, see the magazine's medical section (Hebrew until an English section is live).

How does a person obtain a licence or a prescription?
By turning to an authorized clinician in the relevant field. Depending on the indication and the conditions, approval is given on a prescription track or on an IMCA licence track. A diagnosis does not guarantee approval. The steps and documents can be checked in the process guide on Cannabiz, which is updated in Hebrew.

How is medical use different from non-medical use?
Medical use is allowed only within the approval and its terms. It is not legalization of adult use. The status of non-medical use is explained on The story of cannabis in Israel. An Israeli licence is also not an automatic permit to take cannabis across borders. See the magazine's guide to flying with medical cannabis (currently in Hebrew).

Timeline: medical cannabis in Israel

From the first individual licence in the 1990s to a system that counted 142,000 patients in September 2026, after a peak of 145,700 in August: the three major reforms and the milestones that shaped the industry.

1992. Medical cannabis is regulated for the first time.
The Ministry of Health begins to approve cannabis for medical use in individual cases, mainly for terminally ill patients in palliative care. In the first decade only a few dozen licences were issued.

1993. The first licence in the Rabin government.
The first application for a medical cannabis licence (for hashish) was filed while Haim Ramon was health minister in Yitzhak Rabin's government, and was granted between 1993 and 1994. For years the patient received the hashish from police seizures.

2000–2001. First committees, and home growing.
After discussions in the drugs committee, the Ministry of Health considers imports for the first time and chooses point permits instead. The first licence for home growing for personal use is issued, followed by a number of additional patients.

2006. Dr. Yehuda Baruch and the first company.
Staff work begins on regulated cultivation. The director of Abarbanel Hospital, Dr. Yehuda Baruch, is put in charge of the field, and between 2006 and 2009 he issues commercial cultivation licences, the first of them to Tikun Olam. The number of patients jumps from about 1,000 to about 5,200.

2010. Eight companies, and the first payment.
Eight cultivation and supply companies are operating: Tikun Olam, Sh'ifa Lehaim (later BOL Pharma), Pharmocann, Better, Teva Adir, Canndoc, Seach and IMC. For the first time patients may be charged a fee: 360 shekels a month, later 370.

August 2011. IMCA is established.
Government Decision 3609 regulates «supervision and regulation of a source of supply of cannabis for medical purposes and for research» and establishes the Israel Medical Cannabis Agency (IMCA) in the Ministry of Health. By the end of the year there are about 9,300 licensed patients.

2013–2016. From «Sarel» to the medicalization model.
An attempt to hand the industry to the company Sarel ends in a retreat after growers petition the High Court of Justice. Yuval Landschaft becomes head of IMCA (2013), and Government Decision 1587 (2016) launches the medicalization model: separating the links in the chain and opening the market.

2019. The pharmacy reform.
The reform takes effect: direct contact between the grower and the patient is cut, supply moves through pharmacies, and pricing is by product instead of a uniform fee. The number of patients crosses 50,000.

2020. Prescribing authority is decentralized.
About 94 authorized physicians receive the power to issue licences directly, without a case-by-case IMCA approval, a step that significantly accelerates growth in patient numbers.

January 2024. A peak of 140,000 licences.
The number of active licences reaches a peak of 140,483, a rise of more than 4,400% since 2011. Chronic pain and post-traumatic stress disorder (PTSD) are the most common indications, and flower is the leading product form.

April 2024. The health-fund reform.
Most indications move to a prescription track through the health funds, except chronic pain and PTSD, which remain under IMCA. Tighter controls are followed by a moderate decline in the number of licences.

June 2026. About 146,000 licence and prescription holders.
The number of patients reaches about 145,800: about 112,400 licence holders and about 33,300 prescription holders, according to the IMCA report for June 2026. In parallel, imports, mainly of flower from Canada, continue to grow, and Israel exports medical cannabis on a smaller scale.

September 2026. 142,000 patients, after an August peak.
The IMCA situation report for September 2026, published on 11 November 2026 and reported in article 289059, puts the total at 142,000, down about 3,700 from a peak of 145,700 in August. 107,474 held an active licence and about 34,500 received a prescription through the health funds. The same report's data series puts the June and July totals at 143,700, a figure that differs from the about 145,800 counted in the June 2026 report cited above.

The research that turned cannabis into a medicine

Medical cannabis was not approved as a treatment option because of public pressure alone. Behind the regulation stand six decades of research, a large and central part of it done in Israel, led by Prof. Raphael Mechoulam. These are the scientific milestones that led from the plant to the pharmacy.

1964. THC is isolated.
Prof. Raphael Mechoulam and Yehiel Gaoni, at the Weizmann Institute, isolate THC and work out its structure. For the first time the plant's effects can be studied with precise scientific tools, rather than as an unknown mixture of substances.

1985. The first cannabinoids receive drug approval.
The FDA approves dronabinol (Marinol) and nabilone (Cesamet), synthetic cannabinoids, for nausea and vomiting after chemotherapy. The first proof that cannabis constituents can be approved medicines.

1988–1993. Receptors are found in the brain and the body.
The CB1 receptor is identified in the brain (1988, cloned in 1990), followed by the CB2 receptor in the immune system (1993). This supplied the biological explanation for how cannabis affects the body.

1992–1995. The endocannabinoid system.
Mechoulam's team discovers anandamide (1992) and 2-AG (1995), cannabinoids the body makes itself. The finding explained why the plant has a medical effect at all, and established an entirely new field of research.

2005–2010. A prescription medicine from the plant itself.
Canada approves Sativex (nabiximols), a cannabis extract as a spray, for neuropathic pain in multiple sclerosis; in 2010 it is approved in the United Kingdom for spasticity. This time it is not a synthetic molecule but an extract of the plant.

2013–2021. A wave of Israeli clinical research.
Israel becomes a clinical laboratory: a controlled study on Crohn's disease (2013), CBD in treatment-resistant epilepsy in children (2016), observational studies on thousands of patients, and a controlled study on children on the autism spectrum (2021).

2017. The U.S. National Academies report.
A comprehensive review of hundreds of studies finds substantial evidence of effectiveness in chronic pain, in chemotherapy-induced nausea and vomiting, and in spasticity in multiple sclerosis, while also pointing to considerable knowledge gaps in other indications.

2018. Epidiolex: the first plant-derived FDA approval.
The FDA approves for the first time a medicine derived from the cannabis plant, purified CBD, for rare and severe forms of epilepsy in children (Dravet and Lennox-Gastaut syndromes).

2020. The United Nations recognizes medical value.
Following a World Health Organization recommendation, the U.N. Commission on Narcotic Drugs removes cannabis from the strictest schedule of the 1961 convention, a formal international recognition that the plant has a medical use.

Even so, the research picture is not unequivocal. Most studies of the plant itself are observational and report improvement in pain, sleep and quality of life, while controlled clinical trials, usually done on isolated molecules, show more qualified results. That gap is at the heart of the professional debate, and it is why treatment is always determined and monitored by an authorized clinician.

The plant itself

Before regulation and dosages, this is a plant. A few basic terms help explain what the discussion is actually about.

Flower. The part that is harvested and smoked or vaporized. The flower of the female plant holds most of the active compounds, in tiny resin glands (trichomes) that cover it. This is the most common form in the Israeli market.

Oil and extract. An extraction of the active compounds into oil, taken as drops under the tongue. Its advantages are a more consistent dose and a longer effect, and the fact that it does not involve smoking or vaping.

Indica, sativa and hybrid. A traditional division by the plant's structure, which also became a shorthand for the character of the effect: indica as relaxing, sativa as stimulating. In practice the effect is determined mainly by the composition of active compounds in the specific cultivar, not by the label.

Cannabinoids and terpenes. Cannabinoids (THC, CBD and others) are the main active molecules; terpenes are responsible for smell and taste and also influence the experience. The combination is what gives each cultivar its character.

For more on the plant and its anatomy, and on the indica/sativa distinction, see the information centre on Cannabiz (Hebrew).

In the international arena

Israel is not alone: the medical shift happened in several centres at once, and today also at the federal level in the United States.

  • United States / California, 1996. California passes Proposition 215 and becomes the first U.S. state to approve medical cannabis. In the decades that follow, most states join.
  • Canada, 2001 / 2018. Canada regulates medical access as early as 2001, and in 2018 becomes the first G7 country with federal legalization for adult use. Today it is a major import supplier to Israel.
  • Germany and Europe, 2017 / 2024. Germany opens a broad medical track in 2017, and in 2024 applies a partial legalization, a step with an effect on the entire European cannabis market.
  • United States, federal level, 2024–2025. A historic process advances to reschedule cannabis as having medical use at the federal level, a move that could change the rules in the world's largest market.

The parallel track

The legalization movement and public activism in Israel developed in parallel with the regulation of medical cannabis, not as the force that brought it about. For the story of the ban, enforcement and the campaign to change the law, see The story of cannabis in Israel.

Guides and services on Cannabiz (Hebrew)

What medical cannabis is; the information centre (articles, guides and regulation); licensed doctors; pharmacies; stock lookup; and a shop and product comparison. These tools are in Hebrew.

The information on this page is general background only and is not medical or legal advice, or a substitute for consultation with an authorized professional. The use of medical cannabis in Israel is conditional on a licence or a prescription issued according to law.